Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Jenner

Showing results (111-120 of 177) with videos related to

Pageof 18
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2006
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disabilityMahmoud M Iravani, Kayhan Tayarani-Binazir, Wing B Chu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 29, 2010
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosetsKayhan A Tayarani-Binazir, Michael J Jackson, Sarah Rose, et al.
Expert Review of Neurotherapeutics|September 16, 2021
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicaponePeter Jenner, José-Francisco Rocha, Joaquim J Ferreira, et al.
European Journal of Pharmacology|September 17, 2002
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
The European Journal of Neuroscience|December 11, 2002
Aggresome-related biogenesis of Lewy bodiesKevin St P McNaught, P Shashidharan, Daniel P Perl, et al.
Experimental Neurology|December 31, 2002
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)Eleni C Maratos, Michael J Jackson, Ronald K B Pearce, et al.
Journal of Neurochemistry|February 4, 2009
An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the ratSalma Bukhatwa, Mahmoud M Iravani, Bai-Yun Zeng, et al.
Journal of Neurochemistry|July 15, 2010
The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigraJoanna Iczkiewicz, Lauren Broom, Jonathan D Cooper, et al.
Pageof 18

Showing results (111-120 of 177) with videos related to

Sort By:
Pageof 18
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2006
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disabilityMahmoud M Iravani, Kayhan Tayarani-Binazir, Wing B Chu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 29, 2010
Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosetsKayhan A Tayarani-Binazir, Michael J Jackson, Sarah Rose, et al.
Expert Review of Neurotherapeutics|September 16, 2021
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicaponePeter Jenner, José-Francisco Rocha, Joaquim J Ferreira, et al.
European Journal of Pharmacology|September 17, 2002
Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 20, 2002
Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 27, 2004
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primatesMatthew J Hansard, Lance A Smith, Michael J Jackson, et al.
The European Journal of Neuroscience|December 11, 2002
Aggresome-related biogenesis of Lewy bodiesKevin St P McNaught, P Shashidharan, Daniel P Perl, et al.
Experimental Neurology|December 31, 2002
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus)Eleni C Maratos, Michael J Jackson, Ronald K B Pearce, et al.
Journal of Neurochemistry|February 4, 2009
An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the ratSalma Bukhatwa, Mahmoud M Iravani, Bai-Yun Zeng, et al.
Journal of Neurochemistry|July 15, 2010
The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigraJoanna Iczkiewicz, Lauren Broom, Jonathan D Cooper, et al.
Pageof 18